Fusion Antibodies
Fusion Antibodies is a Belfast-based contract research organization that provides end-to-end antibody discovery, humanization, affinity maturation, and cell line development services to pharmaceutical, biotechnology, and academic clients globally, using proprietary CDRx, RAMP, OptiMAL, and Ab-ility platforms.
- Company typePublic
- Founded2001
- HeadquartersBelfast, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Fusion Antibodies does
Fusion Antibodies plc is a Belfast-based contract research organization founded in 2001 as a spin-out from Queen's University Belfast, listed on the AIM market of the London Stock Exchange under ticker FAB. The company provides end-to-end antibody discovery, engineering, and development services to pharmaceutical and biotechnology clients globally, spanning antigen design, antibody humanization, affinity maturation, developability assessment, transient protein expression, antibody characterization, and stable cell line development through a partnership with Celonic AG.
The company's competitive position rests on four proprietary platforms: CDRx for in silico humanization with a unique guarantee to deliver humanized antibodies within two-fold affinity of parent candidates, RAMP for rational affinity maturation capable of screening approximately 10^25 variants in roughly three weeks, OptiMAL for mammalian-display-based novel antibody discovery launched at a San Diego conference in December 2025, and Ab-ility for in-silico developability and liability engineering. These platforms are augmented by machine learning algorithms developed in partnership with Analytics Engines and underpin a workflow that progresses client assets from animal-derived sequences through to GMP-ready cell lines.
Fusion Antibodies generates revenue primarily through fee-for-service CRO contracts with pharmaceutical and biotechnology clients, supported by IP and asset licensing deals (including a GBP 250,000 agreement with Finn Therapeutics). Customer logos include OncoResponse, Aerpio Therapeutics, Protein Alternatives, NB Health Laboratory, and the National Cancer Institute. Distribution is direct to enterprise R&D leadership in Europe and North America, with exclusive regional partners BioTickle in India and BizCom Japan covering Asia. For FY2026 ending 31 March 2026, reported revenue was GBP 2.13 million, a 9% year-over-year increase, with gross margin expanding from 22% to 50%.
Fusion Antibodies firmographics
Firmographics- Name
- Fusion Antibodies
- Legal name
- Fusion Antibodies plc
- Website
- https://fusionantibodies.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Fusion Antibodies is a Belfast-based contract research organization that provides end-to-end antibody discovery, humanization, affinity maturation, and cell line development services to pharmaceutical, biotechnology, and academic clients globally, using proprietary CDRx, RAMP, OptiMAL, and Ab-ility platforms.
- Ownership category
- akta.pro rank
Fusion Antibodies industry classification
Industry- Product category
- Contract Research Services (Antibody Discovery & Engineering CRO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medical and Diagnostic Laboratories (62151)
- SIC
- Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Fusion Antibodies is headquartered
LocationHeadquarters
- HQ city
- Belfast
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Fusion Antibodies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Services: Fusion Antibodies operates as a contract research organization (CRO) providing fee-for-service antibody discovery, engineering, and development services to pharmaceutical and biotechnology companies. Revenue is generated through project-based contracts for services including antibody humanization, affinity maturation, cell line development, and characterization.
- IP Licensing and Asset Sales: The company generates additional revenue through IP agreements and asset sales, such as the £250,000 IP agreement with Finn Therapeutics for a novel antibody asset.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for antibody development services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Fusion Antibodies product offering
Product offeringCore offering
Fusion Antibodies is a Belfast-based contract research organization that delivers end-to-end antibody discovery, humanization, affinity maturation, developability assessment, transient protein expression, antibody characterization, and stable cell line development services for pharmaceutical and biotechnology clients. Its offering is built on proprietary in silico platforms (CDRx, RAMP, OptiMAL, and Ab-ility) covering the full pre-clinical antibody development workflow from antigen design to GMP-ready cell lines.
Product overview
Fusion Antibodies is a Belfast-based contract research organization (CRO) offering end-to-end antibody discovery and development services as a unified platform. The core offering centers on four interconnected platforms: the CDRx humanization platform for converting animal antibodies to human-like sequences, the RAMP in silico affinity maturation platform for optimizing antibody binding, the OptiMAL mammalian display platform for novel antibody discovery, and the Ab-ility in silico developability platform for lead selection. These platforms are supported by a suite of service modules including antibody humanization (with CDR grafting), antibody reformatting, antibody developability assessment, transient protein expression, antibody characterization, and cell line development. The integrated workflow enables clients to progress antibodies from initial discovery through to GMP-ready clinical trial material.
Differentiator
Problem solved
Functional benefit
Brands
- CDRx™: Proprietary antibody humanization platform combining laboratory experience with in silico techniques.
- RAMP™
- OptiMAL®
- Ab-ility™
Products and services
- Antibody Humanization Services using CDRx Platform Antibody humanization services converting non-human animal antibodies (mouse, rat, rabbit, chicken, llama) into human-like antibodies to avoid immune responses, using CDR grafting techniques combined with T-cell epitope avoidance technologies (ADD) and the CDRx in silico platform, guaranteed to retain affinity within 2-fold of the parent antibody.
- RAMP Rational Affinity Maturation Platform In silico rational affinity maturation platform that creates massive libraries of approximately 10^25 variants of parent antibodies and rapidly screens them in 3 weeks, delivering a micro-library of the 100 best candidates selected for binding potential and stability, reducing affinity maturation timelines from the 3 months typical of mammalian or phage display approaches.
- OptiMAL Mammalian Display Antibody Discovery Platform Human antibody discovery platform using mammalian display technology on a naïve human library designed by Fusion Antibodies to enable novel antibody discovery, with applications in antibody discovery, affinity maturation, and sequence optimisation.
- Ab-ility In-silico Developability Platform Rational in silico developability platform providing in-depth sequence analysis, 3-D modelling, liability engineering, and rapid sequence screening built for lead selection.
- Antibody Reformatting Services Services converting antibodies between different formats (full antibodies, scFvs, Fabs) to meet specific development requirements.
- Transient Protein Expression Services Pilot-scale and scalable transient protein expression services for antibody production and characterization.
- Antibody Characterization Services Comprehensive antibody characterization services including binding assays, activity testing, and biophysical property analysis.
- Cell Line Development Services Stable cell line development services for high-yield production of antibodies, including access via partnership to Celonic CHOvolution cell line technology with stable and high titre (>7g/l) yields.
Quantifiable outcome
- Successfully completed 200th antibody humanization project with affinity within 2-fold difference from parent antibody guaranteed
- +2 more outcomes
Companies that use Fusion Antibodies
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles4 records
Fusion Antibodies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Fusion Antibodies partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered secondary, core and primary.
- Finn Therapeuticssecondary£250,000 IP agreement for novel antibody asset development and licensing.
- National Cancer InstitutecoreProposed extension of collaboration agreement with National Cancer Institute for cancer antibody research and development.
- Eurofins DiscoverysecondaryCo-marketing agreement to support timely and cost-effective development of innovative products for the benefit of global healthcare. Combined service offerings for preclinical drug discovery research.
- BioTickleprimaryExclusive distributor in India providing local biotherapeutic developers access to proprietary antibody discovery, engineering, and cell line development technologies. BioTickle's local knowledge and expertise in biosimilars underpins Fusion's global outreach.
- Queen's University BelfastcoreMultiple collaborations including NICADA (Northern Ireland Coronavirus Antibody Development Alliance) for COVID-19 therapeutic and diagnostic development, Knowledge Transfer Partnerships for software development, and pancreatic cancer drug research. Long-standing partnership with academic researchers including Professor Ultan Power, Professor Chris Scott, and Professor Dan Longley.
- E2DG (Early Drug Development Group)coreStrategic collaboration to provide asset-centric oncology drug discovery companies access to end-to-end service from discovery to manufacturing and preclinical/Phase I/II design. E2DG provides preclinical efficacy and clinical trial expertise.
- ERADA Technology AlliancesecondaryDevelopment of groundbreaking SMAART saliva-based malaria diagnostic test. Fusion Antibodies provides antibody development expertise for detection of novel bio-marker for Plasmodium falciparum parasites.
- Analytics EnginessecondaryStrategic collaboration to incorporate machine learning (ML) and artificial intelligence (AI) into Fusion Antibodies' CDRx humanization platform. Analytics Engines provides expertise to create ML models to continually improve antibody humanization process.
- Protein AlternativessecondaryRevenue share partnership to develop humanized antibodies for therapeutic development. Fusion applies CDRx platform to humanize Protein Alternatives' lead monoclonal antibody PA-0661 for metastatic colorectal cancer.
- NB Health LaboratorysecondaryAlliance for research and licence agreement in monoclonal antibodies targeting GPCRs. Fusion's CDR Multiplex Humanization Platform integrated into NBHL's MoGRA discovery engine for functional antibody generation.
- BizCom JapanprimaryExclusive marketing partnership in Japan for sales and marketing of research reagents, services and equipment to the life science research market. Uses sales and marketing expertise to exclusively market Fusion Antibodies services in Japan.
- Celonic AGsecondaryPartnership for development of high yield stable cell lines. Offers clients direct path to clinical trial material by leveraging Celonic's scale-up capabilities and CHOvolution cell line technology (stable and high titre >7g/l).
- Aerpio TherapeuticssecondarySecond collaboration to apply CDRx Antibody Humanization platform to Aerpio's Mouse Monoclonal Antibody for diabetic eye disease. First project completed in 2015 yielded multiple humanized clinical candidates.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Fusion Antibodies competitors and assessment
Company assessmentBroad incumbents
- GenScript: GenScript is a global biotech CRO/CDMO with extensive antibody discovery, engineering and manufacturing services. Directly comparable to Fusion Antibodies in antibody humanization, affinity maturation and cell line development, but at vastly greater scale.
- Lonza Group: Lonza is a leading global CDMO offering cell line development and biologics manufacturing. Fusion partners with Lonza-adjacent technology (Celonic CHOvolution) and competes for similar antibody development clients at the cell line and bioprocess stages.
- WuXi Biologics: WuXi Biologics is a global CRDMO providing end-to-end antibody discovery, development and manufacturing. Direct overlap with Fusion's service offering but at much larger scale and with integrated GMP manufacturing.
- Charles River Laboratories: Charles River is a large CRO offering discovery and safety assessment services including antibody and cell line development. Overlaps with Fusion Antibodies in pre-clinical antibody workflows but serves a much broader portfolio of services.
- Bio-Techne: Bio-Techne provides reagents, antibodies and assay platforms for life science research. Comparable through its antibody-related product portfolio and protein engineering capabilities, though much larger and more diversified than Fusion.
Direct peers
- Aragen Life Sciences: Aragen is a CRO/CDMO offering antibody discovery, engineering and cell line development. Most directly comparable to Fusion Antibodies by scale, geographic mix (India-led), and full-service antibody platform offering.
- Eurofins Discovery: Eurofins Discovery is a CRO partner of Fusion Antibodies providing pre-clinical drug discovery services including antibody and small molecule research. The companies have an active co-marketing agreement, evidencing overlapping capabilities and client bases.
- AbCellera Biologics: AbCellera is an antibody discovery platform company using high-throughput single-cell screening and AI/ML. Operates a similar technology-and-CRO hybrid model to Fusion Antibodies, with proprietary discovery engines serving pharma and biotech clients.
Emerging players
- Sai Life Sciences: Sai Life Sciences is a mid-sized CRO/CDMO offering discovery, CMC and biologics services. Comparable to Fusion Antibodies in biologics discovery services and target client profile (mid-stage biotechs and pharma), with broader small molecule capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Fusion Antibodies social profiles
Digital presenceFusion Antibodies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fusion Antibodies leadership team
Management profileNumber of profiles
Profiles9 records
Fusion Antibodies funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fusion Antibodies M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fusion Antibodies
What does Fusion Antibodies do?
Fusion Antibodies is a Belfast-based contract research organization that delivers end-to-end antibody discovery, humanization, affinity maturation, developability assessment, transient protein expression, antibody characterization, and stable cell line development services for pharmaceutical and biotechnology clients. Its offering is built on proprietary in silico platforms (CDRx, RAMP, OptiMAL, and Ab-ility) covering the full pre-clinical antibody development workflow from antigen design to GMP-ready cell lines.
Is Fusion Antibodies a public or private company?
Fusion Antibodies is a public company. It is classified as public and is currently operating.
When was Fusion Antibodies founded?
Fusion Antibodies was founded in 2001. It employs 11 to 50 people.
Where is Fusion Antibodies based?
Fusion Antibodies is headquartered in Belfast, United Kingdom, in the Europe region.
How does Fusion Antibodies make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are IP Licensing and Asset Sales.
Who are Fusion Antibodies's main competitors?
Broad incumbents on record are GenScript, Lonza Group, WuXi Biologics, Charles River Laboratories and Bio-Techne. Direct peers are Aragen Life Sciences, Eurofins Discovery and AbCellera Biologics. Sai Life Sciences is listed as an emerging player.
Does Fusion Antibodies have an API?
No public API is recorded for Fusion Antibodies.
What industry is Fusion Antibodies in?
Fusion Antibodies's product category is Contract Research Services (Antibody Discovery & Engineering CRO). Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325412 and its SIC code is 2834.